Zacks Research Has Bullish Forecast for Novavax Q3 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Equities researchers at Zacks Research raised their Q3 2027 EPS estimates for shares of Novavax in a research note issued to investors on Tuesday, July 7th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $0.09 per share for the quarter, up from their previous forecast of $0.08. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Novavax’s current full-year earnings is ($0.19) per share. Zacks Research also issued estimates for Novavax’s Q4 2027 earnings at $0.17 EPS, Q1 2028 earnings at $0.08 EPS, Q2 2028 earnings at $0.08 EPS and FY2028 earnings at $1.41 EPS.

NVAX has been the subject of a number of other reports. Weiss Ratings lowered shares of Novavax from a “hold (c-)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. Jefferies Financial Group restated a “buy” rating on shares of Novavax in a research note on Thursday, March 12th. BTIG Research reiterated a “buy” rating and issued a $19.00 price target on shares of Novavax in a research note on Thursday, June 11th. TD Cowen boosted their price objective on Novavax from $8.00 to $9.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen raised Novavax from a “sell” rating to a “hold” rating in a research note on Sunday, May 31st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $13.00.

Novavax Stock Up 1.2%

Shares of NVAX opened at $9.46 on Wednesday. The business has a 50-day simple moving average of $9.28 and a two-hundred day simple moving average of $8.86. Novavax has a 52 week low of $6.20 and a 52 week high of $11.97. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -16.31 and a beta of 2.43.

Novavax (NASDAQ:NVAX) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.19. The company had revenue of $118.90 million during the quarter, compared to analyst estimates of $79.81 million. Novavax had a negative net margin of 14.73% and a negative return on equity of 14.82%. The firm’s quarterly revenue was down 79.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.93 earnings per share.

Institutional Investors Weigh In On Novavax

Large investors have recently added to or reduced their stakes in the stock. Shah Capital Management boosted its stake in Novavax by 23.3% during the fourth quarter. Shah Capital Management now owns 14,558,780 shares of the biopharmaceutical company’s stock worth $97,835,000 after buying an additional 2,747,000 shares during the period. Farallon Capital Management LLC raised its stake in shares of Novavax by 4,775.0% in the third quarter. Farallon Capital Management LLC now owns 780,000 shares of the biopharmaceutical company’s stock valued at $6,763,000 after acquiring an additional 764,000 shares during the period. UBS Group AG raised its stake in shares of Novavax by 40.3% in the fourth quarter. UBS Group AG now owns 4,894,284 shares of the biopharmaceutical company’s stock valued at $32,890,000 after acquiring an additional 1,405,981 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Novavax by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 15,470,365 shares of the biopharmaceutical company’s stock worth $103,961,000 after acquiring an additional 275,802 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Novavax by 107.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 199,106 shares of the biopharmaceutical company’s stock worth $1,338,000 after purchasing an additional 102,945 shares during the period. 53.04% of the stock is owned by institutional investors.

Key Novavax News

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Zacks Research upgraded Novavax to strong-buy, signaling improved analyst confidence in the stock. Zacks upgrade
• Positive Sentiment: Analysts raised EPS estimates for several upcoming periods, including FY2028 EPS to $1.41 from $1.29, implying a stronger earnings outlook. Zacks estimate increases
• Neutral Sentiment: Novavax has been identified as a trending stock, which may be contributing to trading interest but does not by itself change fundamentals. Trending stock article

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.